Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Sarcopenia and frailty in COPD: Mechanisms, Biomarkers, and Potential Interventions
International Journal of Chronic Obstructive Pulmonary Disease
ISSN: 1178-2005
- View all (3589)
- Volume 19, 2024 (104)
- Volume 18, 2023 (251)
- Volume 17, 2022 (253)
- Volume 16, 2021 (311)
- Volume 15, 2020 (325)
- Volume 14, 2019 (296)
- Volume 13, 2018 (397)
- Volume 12, 2017 (364)
- Volume 11, 2016 (343)
- Volume 10, 2015 (274)
- Volume 9, 2014 (134)
- Volume 8, 2013 (76)
- Volume 7, 2012 (84)
- Volume 6, 2011 (74)
- Volume 5, 2010 (49)
- Volume 4, 2009 (43)
- Volume 3, 2008 (83)
- Volume 2, 2007 (74)
- Volume 1, 2006 (54)
Journal Articles:
- Precision Medicine in COPD (8)
- Psychological distress in COPD – prevalence, impact and management (5)
- Epidemiology, Etiology, and Demography of COPD: Who, When, and How? (6)
- Sarcopenia and frailty in COPD: Mechanisms, Biomarkers, and Potential Interventions (2)
- Personalizing self-management interventions in COPD – Tailoring towards individual preferences, needs, competences, disease characteristics and comorbidities (15)
- Promoting Optimized Health Care for Individuals with COPD in the Era of Telehealth (4)
- Cardiovascular disease and COPD (10)
- Cardiac Safety Tiotropium and Olodaterol (4)
- Volume 11 - 1st World Lung Disease Summit (4)
- Continuing to Confront COPD (3)
Sarcopenia and frailty in COPD: Mechanisms, Biomarkers, and Potential Interventions
Many COPD patients present with an advanced form of age-related muscle impairment, called sarcopenia. In addition, these patients may also exhibit reduced physiological reserves and an increased susceptibility to adverse health outcomes, termed frailty. It is generally well recognized that the presence of sarcopenia and/or frailty in COPD patients increases functional dependency, disease exacerbation, and mortality. Timely recognition and intervention of sarcopenia and frailty are critical for treating COPD. Both these conditions have multifactorial etiologies, necessitating a rigorous characterization of the associated molecular mechanisms and biomarkers before optimal therapeutic interventions are applied. However, the driving molecular mechanisms, biomarkers for identification, and effective therapeutic strategies for sarcopenia and frailty in COPD remain elusive. This Article Collection aims to unravel the molecular and cellular alterations governing pathogenesis of sarcopenia and frailty in COPD.
Multidimensional Frailty Instruments Can Predict Acute Exacerbations Within One Year in Patients with Stable Chronic Obstructive Pulmonary Disease: A Retrospective Longitudinal Study
Wei L, Li P, Liu X, Wang Y, Tang Z, Zhao H, Yu L, Li K, Li J, Du M, Chen X, Zheng X, Zheng Y, Luo Y, Chen J, Jiang X, Chen X, Long H
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:859-871
Published Date: 4 April 2024
Effects of Ninjin’yoeito on Patients with Chronic Obstructive Pulmonary Disease and Comorbid Frailty and Sarcopenia: A Preliminary Open-Label Randomized Controlled Trial
Ohbayashi H, Ariga M, Ohta K, Kudo S, Furuta O, Yamamoto A
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:995-1010
Published Date: 7 May 2024